Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Huitian Blood Products, officially known as Jiangxi Huitian Blood Products Co., Ltd., is a prominent Chinese biopharmaceutical firm specialized in the manufacture of plasma-derived therapies. Headquartered in Nanchang, Jiangxi, the company produces a vital range of products including human albumin, intravenous immunoglobulins, and specific immunoglobulins for hepatitis B, tetanus, and rabies. As a core subsidiary of China Biologic Products Holdings (CBPO), Huitian leverages a robust network of plasma collection stations and advanced fractionation facilities that comply with national Good Manufacturing Practice (GMP) standards. The company's portfolio addresses critical medical needs in fields such as emergency medicine, immunology, and hematology. Huitian maintains a significant market presence within China, contributing to the domestic supply of essential blood-based medications. Its ongoing operations focus on ensuring product safety and expanding its production capacity within the specialized biopharmaceutical sector.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Huitian Blood Products.